Oxurion NV — Director's Dealing 2024

Feb 29, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – February 29, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a first transparency notification on February 28, 2024, from Atlas Special Opportunities, LLC indicating that as of February 26, 2024, it held 199,000,000 shares of the then outstanding 4,938,734,332 shares, and therefore crossed below the threshold (5%) by virtue of the sale of voting securities. See Annex 1.

Oxurion received a second transparency notification on February 28, 2024, from Atlas Special Opportunities, LLC indicating that as of February 28, 2024, it held 90,986,568 shares of the then outstanding 4,938,734,332 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 2.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Oxurion NV	Backstage Communication
Pascal Ghoson	Jurgen Vluijmans
Chief Executive Officer	Partner
Pascal.ghoson@oxurion.com	jurgen@backstagecom.be

For further information please contact:

________

^1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Final
2) Issuer
	Name OXURION
Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name		Address (for legal entities)
	Atlas Special Opportunities LLC		2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name		Address (for legal entities)
o	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6		Part II
7) Date on which the threshold is crossed
		26/02/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		$\overline{5}$
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	4,938,734,332
	Please enter the denominator before filling in the data
			After the transaction
	Previous notification
	# of voting rights		# of voting rights Not linked to the		% of voting rights Not linked to the
10) Notified details A) Voting rights Holders of voting rights		Linked to securities	securities	Linked to securities	securities
Atlas Special Opportunities LLC	543,478,260 TOTAL	199,000,000 199,000,000	$\circ$ $\mathbf{0}$	4.03% 4.03%	0.00%

DocuSign Envelope ID: 1D16A25A-2D16-409A-9217-449C1A7BA072

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							$+1$
	TOTAL			$\Omega$	0.00%
The totals will be updated once you have clicked on Œ
	TOTAL (A & B) # of voting rights % of voting rights
			CALCULATE	199,000,000	4.03%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.
12) In case of proxy voting for only one GM will cease to hold / voting rights as of Holder will hold again	(DD/MM/YYYY)
13) Additional information On 22 February 2024 (with settlement date on 26/02/2024), Atlas Special Opportunities LLC sold 344,478,260 shares in Oxurion NV, as a result of which its shareholding decreased to 199,000,000 shares (= 4.03%, denominator = 4,938,734,332).

Done at New York
On	27/02/2024 (DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder		Signature

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.he. You can do this manually
OR if you have MS Outlook at your disposal via the "Save &
Send" button.

In addition, a signed copy in PDF format should also be
transmitted.

ANNEX 2

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Final
2) Issuer
Name Identification number 0881-620-924	OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
	Downward crossing of the lowest threshold
4) Notification by
	A person that notifies alone						$+$
5) Persons subject to the notification requirement
	Name			Address (for legal entities)
	Atlas Special Opportunities LLC			2500 Westchester Avenue, Suite 401, Purchase, NY 10577			$+$
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name			Address (for legal entities)
							$+$
	Please continue entering the information in part II concerning the Part II persons referred to in Sections 5 and 6
7) Date on which the threshold is crossed
			28/02/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		3
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		4,938,734,332
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification			After the transaction
Holders of voting rights	# of voting rights		Linked to securities	# of voting rights Not linked to the	Linked to securities	% of voting rights Not linked to the
Atlas Special Opportunities LLC	199,000,000		90,986,568	securities $\circ$	1.84%	securities 0.00%	$\left. +\right\vert$
	TOTAL		90,986,568		1.84%

DocuSign Envelope ID: 1D16A25A-2D16-409A-9217-449C1A7BA072

B) Equivalent financial instruments		After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							$+$
	TOTAL
Œ	The totals will be updated once you have clicked on
	TOTAL (A & B)			# of voting rights	% of voting rights
			CALCULATE	90,986,568	1.84%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.
12) In case of proxy voting for only one GM
Holder	(DD/MM/YYYY) will cease to hold / voting rights as of will hold again
13) Additional information
%, denominator = 4,938,734,332).	On 26 February 2024 (with settlement date on 28/02/2024), Atlas Special Opportunities LLC sold 108,013,432 shares in Oxurion NV, as a result of which its shareholding decreased to 90,986,568 shares (= 1.84
Done at New York
28/02/2024 On	(DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder	Signature
	For security reasons, the unsigned form in xlsx format should be transmitted to trp.fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button. In addition, a signed copy in PDF format should also be transmitted.